PRA EU Expansion in Netherlands and UK
The clinical research organisation (CRO), PRA, have announced that they are expanding their European presence with new offices in both the Netherlands and the UK.
The additional space was required to house the growing number of PRA employees and the large demand for PRA’s Phase IIa-IIIb service offerings, the CRO noted.
Recently the company has signed a variety of major deals, including a biosimilar research agreement with Amgen, and an international drug development partnership with UCB.
The new Dutch facility will be located in Utrecht, and will accommodate over 20 employees, and become the first PRA workplace in the region which is focused mainly on clinical trials for product registration.
Employees from three alternative PRA office locations in the Netherlands (Zuidlaren, Groningen and Assen) currently support early-development and laboratory studies.
In the past the corporation’s product-registration employees in the Netherlands were either home-based or shared offices with PRA staff in Mechelen, Belgium.
“But to better share best practices among employees, we felt that it was now necessary to provide a permanent office for the increasing Dutch Product Registration team,” commented Frank van de Wijngaert, PRA’s vice president and general partner.
The clinical research organisation’s 240-plus workforce in Reading, UK have moved to a bigger PRA-designed office, which offers space for future staff growth, alongside modern amenities for project team and client meetings.
Since 2009, PRA have opened nine new offices across Europe, including a Romanian base in August last year, and new Singapore offices earlier this year, “demonstrating our commitment to meeting our clients’ diverse needs in a dynamic clinical trials environment”, the organisation stated.